Several brokerages have updated their recommendations and price targets on shares of Metagenomi (NASDAQ: MGX) in the last few weeks:
- 7/20/2026 – Metagenomi was upgraded by Wall Street Zen from “strong sell” to “sell”.
- 7/12/2026 – Metagenomi was downgraded by Wall Street Zen from “sell” to “strong sell”.
- 7/8/2026 – Metagenomi was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 7/7/2026 – Metagenomi is now covered by Chardan Capital. They set a “buy” rating and a $5.00 price target on the stock.
- 6/23/2026 – Metagenomi was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 6/15/2026 – Metagenomi was upgraded by Wall Street Zen from “strong sell” to “sell”.
- 6/8/2026 – Metagenomi was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 5/30/2026 – Metagenomi was upgraded by Wall Street Zen from “strong sell” to “sell”.
Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.
Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.
See Also
- Five stocks we like better than Metagenomi
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Metagenomi Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi Inc and related companies with MarketBeat.com's FREE daily email newsletter.
